BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22024769)

  • 21. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.
    Paoluzzi L; Scotto L; Marchi E; Zain J; Seshan VE; O'Connor OA
    Clin Cancer Res; 2010 Jan; 16(2):554-65. PubMed ID: 20068080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.
    Fernàndez V; Hartmann E; Ott G; Campo E; Rosenwald A
    J Clin Oncol; 2005 Sep; 23(26):6364-9. PubMed ID: 16155021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. bcl-1 rearrangement and cyclin D1 protein expression in mantle cell lymphoma.
    Ott MM; Helbing A; Ott G; Bartek J; Fischer L; Dürr A; Kreipe H; Müller-Hermelink HK
    J Pathol; 1996 Jul; 179(3):238-42. PubMed ID: 8774476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of cyclin D1 and CD20 mRNA levels by real-time quantitative RT-PCR from archival tissue sections of mantle cell lymphoma and other non-Hodgkin's lymphomas.
    Thomázy VA; Luthra R; Uthman MO; Davies PJ; Medeiros LJ
    J Mol Diagn; 2002 Nov; 4(4):201-8. PubMed ID: 12411587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
    Hess G; Smith SM; Berkenblit A; Coiffier B
    Semin Oncol; 2009 Dec; 36 Suppl 3():S37-45. PubMed ID: 19963099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.
    Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE
    Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease.
    Nguyen PL; Harris NL; Ritz J; Robertson MJ
    Am J Pathol; 1996 Mar; 148(3):847-53. PubMed ID: 8774139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
    Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
    Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endocannabinoids in the immune system and cancer.
    Parolaro D; Massi P; Rubino T; Monti E
    Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):319-32. PubMed ID: 12052046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
    Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
    Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cellular origin of mantle cell lymphoma.
    Bertoni F; Ponzoni M
    Int J Biochem Cell Biol; 2007; 39(10):1747-53. PubMed ID: 17574898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of mantle cell lymphoma: targeting the microenvironment.
    Drach J; Seidl S; Kaufmann H
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):477-85. PubMed ID: 16001955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
    Smedby KE; Hjalgrim H
    Semin Cancer Biol; 2011 Nov; 21(5):293-8. PubMed ID: 21945518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. WIN55,212-2 induces cytoplasmic vacuolation in apoptosis-resistant MCL cells.
    Wasik AM; Almestrand S; Wang X; Hultenby K; Dackland ÅL; Andersson P; Kimby E; Christensson B; Sander B
    Cell Death Dis; 2011 Nov; 2(11):e225. PubMed ID: 22048168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Mantle cell lymphoma (MCL)--histopathology and clinical features].
    Fakan F; Plank L; Szépe P; Kocová L
    Cesk Patol; 1998 Apr; 34(2):47-53. PubMed ID: 9624825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Cannabidiol, ∆9-Tetrahydrocannabinol, and WIN 55-212-22 on the Viability of Canine and Human Non-Hodgkin Lymphoma Cell Lines.
    Omer S; Pathak S; Mansour M; Nadar R; Bowen D; Dhanasekaran M; Pondugula SR; Boothe D
    Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endocannabinoids and Cancer.
    Velasco G; Sánchez C; Guzmán M
    Handb Exp Pharmacol; 2015; 231():449-72. PubMed ID: 26408171
    [TBL] [